Fernand Labrie

Publications

Page 5 of 9, showing 50 records out of 429 total, starting on record 201, ending on 250

Publication Category Year
88. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. Intracrinology 1997
439. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. Intracrinology 1997
440. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long-term inhibitory effects of a novel anti-estrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. Intracrinology 1997
441. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. Intracrinology 1997
442. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. Intracrinology 1997
443. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. Intracrinology 1997
864. Luu-The, V., Simard, J., Labrie, C., Bélanger, A., Labrie, F. (1997) Intracrinology and hormone-dependent cancers. Rev. Clin. Pharmacol., 11: 18-26. Intracrinology 1997
865. Poulin, M.-J., Simard, J., Catford, J.-G., Labrie, F., Piché, Y. (1997) Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens. Mol. Plant. Microbe Interactions, 10: 481-487. Intracrinology 1997
444. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. Intracrinology 1997
89. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. Intracrinology 1997
445. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. Intracrinology 1997
90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. Intracrinology 1997
447. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. Intracrinology 1997
448. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. Intracrinology 1997
91. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. Intracrinology 1996
450. Blais, Y., Gingras, S., Haagensen, D.E., Labrie, F., Simard, J. (1996). Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol., 121: 11-18. Intracrinology 1996
874. Chen, C., Bélanger, A., Labrie, F. (1996) Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Endocrinology, 137: 1752-1757. Intracrinology 1996
92. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. Intracrinology 1996
94. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. Intracrinology 1996
363. Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Labrie, F. (1996) Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol., 150 Suppl.: S43-S50. Intracrinology 1996
95. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. Intracrinology 1996
879. Dufort, I., Tremblay, Y., Bélanger, A., Labrie, F., Luu-The, V. (1996) Isolation and characterization of a stereospecific 3beta-hydroxysteroid sulfotransferase (pregnenolone sulfotransferase) cDNA. DNA Cell Biol., 15: 481-487. Intracrinology 1996
96. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. Intracrinology 1996
99. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: Intracrinology 1996
101. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. Intracrinology 1996
103. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. Intracrinology 1996
884. Labrie, F., Simard, J., Luu-The, V., Bélanger, A., Pelletier, G., Morel, Y., Mebarki, F., Sanchez, R., Durocher, F., Turgeon, C., Labrie, Y., Rhéaume, E., Labrie, C., Lachance, Y. (1996) The 3beta-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3beta-HSD congenital deficiency, in: Proceeding 9th European Testis Workshop Signal Transduction in Testicular Cells - Basic and Clinical Aspects, Springer-Verlag, pp 185-218. Intracrinology 1996
104. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. Intracrinology 1996
886. Li, X., Singh, S.M., Luu-The, V., Côté, J., Laplante, S., Labrie, F. (1996) Vinyl fluoride as a mimic of the "intermediate" enol form in the 5alpha-reductase transformation: synthesis and in vitro activity of (N-1',1'-dimethylethyl)-3-haloandrost-3,5-diene-17beta-carboxamides. Bioorg. Med. Chem., 4: 55-60. Intracrinology 1996
887. Lin, S.-X., Zhu, D.-W., Azzi, A., Campbell, R.L., Breton, R., Labrie, F., Ghosh, D., Pletnev, V., Duax, W.L., Pangborn, W. (1996) Studies on the 3D-structure of estrogenic 17beta-hydroxysteroid dehydrogenase. J. Endocrinol., 150 Suppl.: S13-S20. Intracrinology 1996
888. Lopez-Solache, I., Luu-The, V., Séralini, G.E., Labrie, F. (1996) Heterogeneity of rat type I 5alpha-reductase cDNA: cloning, expression and regulation by pituitary implants and dihydrotestosterone. Biochim. Biophys. Acta, 1305: 139-144. Intracrinology 1996
889. Luu-The, V., Bernier, F., Dufort, I., Labrie, F. (1996) Molecular biology of steroid sulfotransferase. Ann. N.Y. Acad. Sci., 784: 137-148. Intracrinology 1996
890. Morissette, J., Durocher, F., Leblanc, J.-F., Normand, T., Labrie, F., Simard, J. (1996) Genetic linkage mapping of the human steroid 5alpha-reductase type 2 gene (SRD5alpha2) close to D2S352 on chromosome region 2p22-23. Cytogenet. Cell. Genet., 73: 304-307. Intracrinology 1996
454. Poirier, D., Mérand, Y., Labrie, C., Labrie, F. (1996) D-Ring alkylamide derivatives of estradiol: Effect on ER-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett., 6: 2537-2542. Intracrinology 1996
892. Simard, J., Durocher, F., Mébarki, F., Turgeon, C., Sanchez, R., Labrie, Y., Couet, J., Trudel, C., Rhéaume, E., Morel, Y., Luu-The, V., Labrie, F. (1996) Molecular biology and genetics of the 3beta-hydroxysteroid dehydrogenase/delta5/delta4 isomerase gene family. J. Endocrinol., 150 Suppl.: S189-S207. Intracrinology 1996
893. Simard, J., Rhéaume, E., Sanchez, R., Mebarki, F., Morel, Y., Zerah, M., New, M.I., Labrie, F. (1996) Relation between molecular defect and phenotypic manifestation of human 3beta-hyroxysteroid dehydrogenase deficiency, in: New, M., ed. Frontiers Endocrinol., Serono Symposia Series, pp 39-68. Intracrinology 1996
631. Tchernof, A., Labrie, F., Bélanger, A., Després, J.P. (1996) Obesity and metabolic complications: contribution of DHEA and other steroid hormones. J. Endocrinol, 150: S155-S164. Intracrinology 1996
106. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. Intracrinology 1996
107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. Intracrinology 1996
456. Auger, S., Mérand, Y., Pelletier, J.D., Poirier, D., Labrie, F. (1995) Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384. J. Steroid Biochem. Mol. Biol., 52: 547-565. Intracrinology 1995
457. Blais, Y., Sugimoto, K., Carrière, M.C., Haagensen, D.E., Labrie, F., Simard, J. (1995) Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Int. J. Cancer, 62: 732-737. Intracrinology 1995
632. Dalla Valle, L., Couet, J., Labrie, Y., Simard, J., Belvedere, P., Simontacchi, C., Labrie, F., Colombo, L. (1995) Occurrence of cytochrome 450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract. Mol. Cell. Endocrinol., 111: 83-92. Intracrinology 1995
900. Doualla-Bell, F., Bonneau, M.J., Labrie, F., Fortier, M.A. (1995) Differential effects of a steroidal antiestrogen, EM-139, on prostaglandin and cAMP production in the circular and longitudinal layers of bovine myometrium. Biol. Reprod., 52: 1358-1363. Intracrinology 1995
901. Durocher, F., Morissette, J., Labrie, Y., Labrie, F., Simard, J. (1995) Mapping of the HSD17B2 gene encoding type II 17beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q 24.1-q24.2. Genomics, 25: 724-726. Intracrinology 1995
902. Ghosh, D., Pletnev, V.Z., Zhu, D.-W., Wawrzak, Z., Duax, W.L., Pangborn, W., Labrie, F., Lin, S.-X. (1995) Structure of human estrogenic 17beta-hydroxysteroid dehydrogenase at 2.20 a resolution. Structure, 3: 503-513. Intracrinology 1995
903. Guérin, S.L., Leclerc, S., Verreault, H., Labrie, F., Luu-The, V. (1995) Overlapping cis-acting elements located in the first intron of the gene for type I 3beta-hydroxysteroid dehydrogenase modulate its transcriptional activity. Mol. Endocrinol., 9: 1583-1597. Intracrinology 1995
634. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. N.Y. Acad. Sci., 774: 16-28. Intracrinology 1995
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. Intracrinology 1995
112. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. Intracrinology 1995
459. Labrie, F., Li, S., Labrie, C., Lévesque, C., Mérand, Y. (1995) Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 33: 237-244. Intracrinology 1995
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards